Thursday, October 24, 2013


Community Oncologist Education and Support Systems
Renal Cell Carcinoma and Hematologic Malignancies
Request for Proposals
National Comprehensive Cancer Network and
Pfizer Independent Grants for Learning & Change

Pfizer and National Comprehensive Cancer Network (NCCN) are collaborating
 to offer a new grant opportunity focused on improving care for patients with 
rare types of cancer such as renal cell carcinoma (RCC) and certain hematologic
 malignancies, where treatment options are complex and rapidly advancing.

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is 
to accelerate the adoption of evidence‐based innovations that align the mutual
 interests of patients, healthcare professionals, and Pfizer, through support 
of independent professional education activities. The term “independent”
 means the initiatives funded by Pfizer are the full responsibility of the
 recipient organization. Pfizer has no influence over any aspect of the initiatives,
 and only asks for reports about the results and impact of the initiatives, 
which it may share publicly.

NCCN, a not‐for‐profit alliance of twenty‐three (23) of the world’s leading
 cancer centers, is dedicated to improving the quality and effectiveness of
 care provided to patients with cancer. Through the leadership and expertise
 of clinical professionals at NCCN Member Institutions, NCCN develops 
resources that present valuable information to the numerous stakeholders
 in the health care delivery system. NCCN has access, through its member
 institutions, to the world’s leading thought leaders in all areas and aspects 
of oncology who are integral to the execution of this program.

This Request for Proposals (RFP) is being issued by both organizations. NCCN is
 the lead organization for review and evaluation of applications. A review
 committee, led by NCCN, will make decisions on which proposals will receive
 funding. Grant funding will be provided by Pfizer. Collectively, up to $2 million 
is available for the program.

Once announced through this distribution list, the RFP will also be 
posted on our website at  Please
 refer to the full text of the RFP for various key dates and submission 

Clinical Areas:
Category 1: Oncology Communities – RCC
Category 2: Oncology Communities –
 Hematologic Malignancies
LOI Due Date:
December 5, 2013

Please send an email to to unsubscribe from this distribution.

Post a Comment